Skip to main content

Table 1 Results for patients with PCR confirmed Plasmodium falciparum malaria at enrolment

From: Assessment of the therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in northern KwaZulu-Natal: an observational cohort study

Age

Gender

Travel 60 days prior to illness

Temp

mdr1copy number (lumefantrine sensitivity)

mdr1N86Y gene (chloroquine sensitivity)

Chloroquine resistance transporter genecrtK76T codons 72-76

Follow-up day

Follow-upP. falciparummalaria PCR

40

Female

Mozambique

36.5

1

Asparagine (mdr1 86N)

CVMNK

28

Negative

7

Male

Not recorded

39.4

1

asparagine

CVMNK and CVIET

191

Negative

32

Female

None

36.4

1

asparagine

CVIET

168

Insufficient sample

24

Male

None

39.3

1

asparagine

CVMNK

49

Negative

9

Female

Not recorded

Not recorded

1

asparagine

CVMNK

29

Negative

31

Male

Mozambique

38.3

1

asparagine

CVMNK

32

Negative

8

Female

None

36.7

1

asparagine

CVIET

29

Negative

15

Male

Mozambique

38.0

1

asparagine

CVIET

106

Negative

20

Male

Mozambique

41.0

1

asparagine

CVMNK

127

Negative

37

Female

Not recorded

38.7

1

asparagine

CVMNK

86

Negative

6

Female

None

39.0

1

asparagine

CVMNK

28

Negative

2

Female

Mozambique

Not recorded

1

asparagine

CVMNK

NA

Lost to follow-up; returned to Mozambique

17

Male

None

38.2

1

asparagine

CVMNK

69

Negative

14

Female

None

38.0

1

asparagine

CVMNK

92

Negative

4

Female

Mozambique

38.0

1

asparagine

CVMNK

59

Negative

3

Male

Not recorded

38.0

1

asparagine

CVMNK

57

Negative